CA1192821A - High glucose-determining analytical element - Google Patents
High glucose-determining analytical elementInfo
- Publication number
- CA1192821A CA1192821A CA000425034A CA425034A CA1192821A CA 1192821 A CA1192821 A CA 1192821A CA 000425034 A CA000425034 A CA 000425034A CA 425034 A CA425034 A CA 425034A CA 1192821 A CA1192821 A CA 1192821A
- Authority
- CA
- Canada
- Prior art keywords
- solution
- liter
- salt
- hydroxy
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/28—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/521—Single-layer analytical elements
- G01N33/523—Single-layer analytical elements the element being adapted for a specific analyte
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/525—Multi-layer analytical elements
- G01N33/526—Multi-layer analytical elements the element being adapted for a specific analyte
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2326/00—Chromogens for determinations of oxidoreductase enzymes
- C12Q2326/50—Phenols; Naphthols; Catechols
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2326/00—Chromogens for determinations of oxidoreductase enzymes
- C12Q2326/90—Developer
- C12Q2326/96—4-Amino-antipyrine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/805—Test papers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
- Y10T436/144444—Glucose
Abstract
ABSTRACT
An analytical element for quantitatively determining high levels of glucose in blood is made by (a) impregnating a carrier with a first-solution, having dissolved therein 4-aminoantipyrine and 3-hydroxy-2,4,6-triiodobenzoic acid or 3,5 dichloro-2-hydroxy-benzene sulfonic acid or salts thereof, a glucose oxidase and a peroxidase, and drying the carrier; and (b) applying to the carrier a second solution of a film-forming agent in a volatile solvent, and drying to remove the volatile solvent and leave a film over the dried first impregnant.
An analytical element for quantitatively determining high levels of glucose in blood is made by (a) impregnating a carrier with a first-solution, having dissolved therein 4-aminoantipyrine and 3-hydroxy-2,4,6-triiodobenzoic acid or 3,5 dichloro-2-hydroxy-benzene sulfonic acid or salts thereof, a glucose oxidase and a peroxidase, and drying the carrier; and (b) applying to the carrier a second solution of a film-forming agent in a volatile solvent, and drying to remove the volatile solvent and leave a film over the dried first impregnant.
Description
-- 2 ~
BACKGROUMD OF T~IE II~VENTION
1. FIELD OF THE INVENTION
The present invention relates g~nerally to the field of diagnostic tests and, more particularly, to te6t devices and elements useful in the.qualltit:ative determination of ~n analyte havint3 a high glucosq content.
BACKGROUMD OF T~IE II~VENTION
1. FIELD OF THE INVENTION
The present invention relates g~nerally to the field of diagnostic tests and, more particularly, to te6t devices and elements useful in the.qualltit:ative determination of ~n analyte havint3 a high glucosq content.
2. BRIEF DESCRIPTION OE' T~IE PRIOR ART
~ est devices in th~ form of test strips a~d similar solid phase analytical e~ements have become commonplace in the analysis of various types of samples, particularly biological fluids. Test strips designed for detecting sugar, i.e., glucose, in biological fluidsl such as serum and urine, have been advantageous in the diagnosis of disease.
U~S. Patent No. 4/273~868~ commonly assigned herewith, discloses a composition, a test device, a method of makinq the test device and a process for determining glucose in a sample. The test composition comprises glucose oxidase, a peroxidatively active substance such ~s peroxidase, a ~0 stabilizing agent and-~ 3,3',5,5'-tetraalkylbenzidine indicator in an amount suf f iciPnt to rapidly produce; upon contact of the test means with a predetermined amount of a glucose-containing sample, a stable colored re~ction product believed to comprise reduced and ~xidized forms of said indicator in stable equilibrium. Preferably9 3,3',5,~'-tetramethylbenzidine is present in a concentration of at least about 2.6 millimoles per thousand International Units of glucose oxidase activity. One of the disclosed ~tabilizing agents is an interpolymer of methylYinyl ethPr 30 and maleic anhydride~ marketed commerically as Gantrez ~,i ~, MS-1235 C ~
* Trade Mark AN-139 by GAF Corporation. The tes-t devices are prepared by a two-dip impregnation process where the 3,3 ', 5,5'--tetraalkylbenzidine is impregnated in the second dip us-ing a solution -thereof prepared in an organic solvent.
U.S. Patent No. 4,361,648 discloses an improvement thereover wherein a carrier is impregnated with an aque-ous solution of tetraalkylbenzidine dihydrochloride and polymeric mordant and dried, then impregnated with a solution of a glucose oxidase and peroxidase, and then impregnated with a solution oE a film-forming agent in a volatile solvent. Such test strip i5 quite satisfactory for the instrumental determination oE glucose levels from 0-4000 milligrams per liteE (mg/liter). Such strip, how-ever, is not suitable for visual determination of rela-tively high glucose levels since the color differences are inadequate.
Barham and Trinder in Analyst, February 1972, Vol.
97, pages 142-145, Trinder in Ann. Clin. Biochem, 6 (1969) 24-27, and Fossati et al in Clin. Chem, 26/2 (1980) 227-231 discuss using 4-aminoantipyrine as a color coupler with 3,5-dichlorohydroxybenzensulfonic acid in determining glucose levels using glucose o2~idase/perox-idase system. This test is a liquid assay and is used primarily for glucose concentration between 0-4000 mg/
:Liter. In this test, whole blood is added to a protein precipitant solution and centrifuged. The clear fluid is added to the color reagent, incubated at 30C for 15 minutes and then the optical density is read at 515 nan~
ometers ~nm) by a spectrophotometer. This liquid system results in expected kinetics and is slow.
It is accordingly an object of the invention to pro-vide an improved test strip which involves an atypical kinetic system, reacts quickly to permit visual quanti-tative glucose determination over the range from about 2000 to 8000 mg/liter, and which strip is simple and in-expensive to prepare.
~. ~.#~
SUM~IARY OF TEIE :[NVENTION
These and other objects and advantages are realized in accordance with the present invention pursuant to which there is provided an analytical element prod~lced by the 5 steps of (a) impregnating a carrier with a firs-t solution, having dissolved therein 4-am:inoantipyrine, or a salt thereof, and 3 hydroxy-2,4,6~triiodo~benzoic acid or
~ est devices in th~ form of test strips a~d similar solid phase analytical e~ements have become commonplace in the analysis of various types of samples, particularly biological fluids. Test strips designed for detecting sugar, i.e., glucose, in biological fluidsl such as serum and urine, have been advantageous in the diagnosis of disease.
U~S. Patent No. 4/273~868~ commonly assigned herewith, discloses a composition, a test device, a method of makinq the test device and a process for determining glucose in a sample. The test composition comprises glucose oxidase, a peroxidatively active substance such ~s peroxidase, a ~0 stabilizing agent and-~ 3,3',5,5'-tetraalkylbenzidine indicator in an amount suf f iciPnt to rapidly produce; upon contact of the test means with a predetermined amount of a glucose-containing sample, a stable colored re~ction product believed to comprise reduced and ~xidized forms of said indicator in stable equilibrium. Preferably9 3,3',5,~'-tetramethylbenzidine is present in a concentration of at least about 2.6 millimoles per thousand International Units of glucose oxidase activity. One of the disclosed ~tabilizing agents is an interpolymer of methylYinyl ethPr 30 and maleic anhydride~ marketed commerically as Gantrez ~,i ~, MS-1235 C ~
* Trade Mark AN-139 by GAF Corporation. The tes-t devices are prepared by a two-dip impregnation process where the 3,3 ', 5,5'--tetraalkylbenzidine is impregnated in the second dip us-ing a solution -thereof prepared in an organic solvent.
U.S. Patent No. 4,361,648 discloses an improvement thereover wherein a carrier is impregnated with an aque-ous solution of tetraalkylbenzidine dihydrochloride and polymeric mordant and dried, then impregnated with a solution of a glucose oxidase and peroxidase, and then impregnated with a solution oE a film-forming agent in a volatile solvent. Such test strip i5 quite satisfactory for the instrumental determination oE glucose levels from 0-4000 milligrams per liteE (mg/liter). Such strip, how-ever, is not suitable for visual determination of rela-tively high glucose levels since the color differences are inadequate.
Barham and Trinder in Analyst, February 1972, Vol.
97, pages 142-145, Trinder in Ann. Clin. Biochem, 6 (1969) 24-27, and Fossati et al in Clin. Chem, 26/2 (1980) 227-231 discuss using 4-aminoantipyrine as a color coupler with 3,5-dichlorohydroxybenzensulfonic acid in determining glucose levels using glucose o2~idase/perox-idase system. This test is a liquid assay and is used primarily for glucose concentration between 0-4000 mg/
:Liter. In this test, whole blood is added to a protein precipitant solution and centrifuged. The clear fluid is added to the color reagent, incubated at 30C for 15 minutes and then the optical density is read at 515 nan~
ometers ~nm) by a spectrophotometer. This liquid system results in expected kinetics and is slow.
It is accordingly an object of the invention to pro-vide an improved test strip which involves an atypical kinetic system, reacts quickly to permit visual quanti-tative glucose determination over the range from about 2000 to 8000 mg/liter, and which strip is simple and in-expensive to prepare.
~. ~.#~
SUM~IARY OF TEIE :[NVENTION
These and other objects and advantages are realized in accordance with the present invention pursuant to which there is provided an analytical element prod~lced by the 5 steps of (a) impregnating a carrier with a firs-t solution, having dissolved therein 4-am:inoantipyrine, or a salt thereof, and 3 hydroxy-2,4,6~triiodo~benzoic acid or
3,5~dichloro-2-hydroxy-ben~ene sulfonic acid, or salts 10 ~hereof, a glucose oxidase and a peroxidase, and dryin~ the carrier; and (b3 applying to the carrier a second solution of a film-forming agent in a volatile solvent, and drying to remove the volatile solvent and leave a f1lm over the dried 15 first impregnant.-In accordance with another aspect of the invention,such an element is used in conjunction with a conventional second element which quantifies glucose contents below about 1800 mg/liter. Thus, if the second element indicates a 20 ylucose level beyond its xange the technician -then uses the fi~st element.
Likewise there i5 provided an analytical element and method for the determination of an analyte in a fluid sample which comprises contacting a sample with the analytical 25 element according to the invention and observing any resultant color change. The colored reaction product is produced within a time period of about 60-90 seconds after contact of the analytical element with the body fluid sample to be tested.
DESCRIPTION OF T~IE PRE~F~RRED EMB~DIMENTS
Although specific terms are used in the following description for the sake of clarity, these terms are intended to refer only to the particular embodiment of the 5 invention selected for exemplary illustration, and are no-t intended to define or limit the scope of the invention.
ANALYTE~RESPONSIVE COMPONENT
The analyte-responsive component comprises those reagents which interact with the analyte and/or resulting 10 products thereof to produce an oxidizing substance, e.g., hydrogen peroxide. In the presence of a peroxidatively active substance, which is one reagent of the analyte-responsive component, the oxidizing substance oxidizes the indicator to produce a detectable species 15 thereof.
rrhe indicator coupling agent comprises 4-aminoanti-pyrine~AAP) and 3,5-dichloro-2-hydroxy-benzene sulfo~ic acid and salts thereof. As an alternative, 3-hydroxy~2,4,6-triiod~benzoic acid (mw 515.8) can be 20 su~stituted for the 3,5-dichloro-2-hydroxy-benzene sulfonic acid.Attempts to use tetraalkylbenzidines as the indicator were unsuccessful because they lack the necassary reaction kinetics properties. 3-Methyl-2-benzothiazolinone hydrazone(MBTH3 with primiquine diphosphate was unsuitable.
25 4-aminoantipyrine with coupling agents 3-hydroxy-1,2,3,4-tetrahydrobenzo(n)quinoline(HTBQ~, methyl catechol, primiquine diphosphate and phenothiazine was also unsuitable.
The combination of 4-aminoantipyrine and 3,5-dichloro 30 2-hydroxy-benzene sulfonic acid, and the sodium or potassium salts thereof, performs successfully and best at particular ratios, as well as enzyme levels, buffer concentrations and polymer mo:rdants to monitor the color formation so that 3~
essentially no color is genera-ted with a glucose concentration less than 1800 mg/liter and then a sliyht peach color starts to form around 2000 mg/liter and continues to produce more color until 8000 mg/liter. As a result, good color resolution exists in every adjacent color block~
POLYMERIC MORDANT
Suitable polymeric mordants which can be used include poly(carboxylic acids) having the formula:
lo t (c~ c ~o ~ / n wherein R is a C1 Cl8 alkyl or amide, and n is an in-teger from 2 to the total number o~ repeating units of the polymer. Examples include polyacrylic acid and polyacrylamide copolymer.
Other polymeric mordants which can be used are copolymeric anhydrides having tne formula:
H R H H
C = C~ C = C
' O = C C ~
/
~1 wherein R i5 C1-Cl8 alkyl, ether, acetate or benzyl and n is an integer from 2 to the total number of repeating units of the polymer. Examples-include methyl vinyl e-ther maleic anhydride copolymer; vinyl acetate-maleic anhydride copolymer; ethylene-maleic anhvdride copo]ymer; octadecyl vinyl ether-maleic anhydride copolymer; and styrene maleic anhydride copolymer.
The polymeric mordant is preferably present in a concerltration o~ from about 0.5 to about 0.75 percen-t of the composition on a weight -to weight basis.
CARRIER
The term carrier refers -to matrices which are in-solu~le in and maintain their structural in~egrity when exposed to physiological or other liquid to be tested.
Suitable matrices which can be used include paper, cel-lulose, wood, synthetic resin fleeces, glass -Eiber, non-woven and woven fabrics, gelatin, various organic poly-mers, such as polypropylene/ and other organic materials well known as film ormers to those skilled in the art.
For convenience, th~ carrier can be suitably attached to an insoluble support or handle member which can be made from polystyrene~
ELEMENT PREPARATION
~s recited hereinabove, the test device is prepared by a process which comprises impregnating the carrier with a first solution having dissolved therein the indica-tor-coupling agent and a glucose oxidase-peroxidase. The glu-cose oxidase-peroxidase is described more fully in U.S.
Patent No. 4,361,648.
Using Whatman 3MM paper, the concentration of the 4-aminoantipyrine or salt thereof in the first solution is from about 5 to 40, preferably about lO to 30, and most preferably about 15 millimoles/liter(mmoles/liter), while the concentration of the 3,5-dichloro-2-hydroxy-benzene sulfonic acid or salt thereoE is from abou-t 0.5 to 500, preferably about 1 to 50, and mos-t pre~erably about 6 mmoles/liter.
* Trade Mark "~
The solution is advan~acJeously buEfered -to a p~l of ,about 5 to 8, preEerab~y about 7, employing a known noninterfering bu~fer such as tris~malonate. Citrate or any other buffer which will provide the same pH range can be 5 used.
Drying is of course eEfected as quickly as possible.
The second step in element preparation comprises impregnating the carrier with a solution of a semi-permeable polymer, such as ekhyl cellulose, in an organic solvent and 10 drying the carrierO The or~anic solvent preferably includes toluene. Particularly pref~rred is an organic solvent which includes toluene and ethanol. Where the solvent conslsts essentially of toluene ~nd ethanol, the toluene is Erom about 80 to 95 percent of the solvent and the ethanol is 15 from about 5 to a~out 20 percent of the solvent, the toluene and ethanol being together 100 percent on a volume/volume basis~
Suitable film-Eorming agents include other hydrophobic cellulose ethers and esters, the film serving to prevent 20 formed eleme,nts (red blood cell9~ from absorbing into the carrier during the period of use.
AN~LYTICAL PROCEDURE
The test device is advantageously used b,y momentarily dipping it in a test sample or by otherwise introducing a 25 test sample onto the carrier matrix, whereby a de-tectable color changè results when glucose is present. The volumetric capacity of khe carrier serves to limit the amount of sample absorbed thereby and to which the kest means incorporated therewith is exposed. Any excess sample 30 can be removed by washing the carrier to thereby limit the amount of sample tested to the volume thereof which has actually entered the carrier matrix. The liqui~ medium to M'~ 35 be assayed can be a naturally occurring or artificially formed liquid suspected to contain ~he ligand, and usually is a biologoical fluid or dilution thereof. siological _ fluids -that can be assayed includ,e serum, plasma, urine, 5 saliva, and amniotic and cerebrospinal fluids. The tes-t device can be used in the same way when samples of plasma, serum or o-ther body fluids are tested.
Semi quantitative results can be obtained using the analytical, elemen-t of the p~esen-t :inVentiOIl by compa-rlng tlle 10 color produced with a panel of standard colors ohtained with known concen-trations o~ analyte employing the same indicator~
The key issue invo~ving the chemistry of the novel elemen~s is -that i~ yields reaction kinetics which are lS atypical compared to tes-t systems with other indicators in solid or liquid-phase; and even the same components in liquid-phase or in solid-phase with a different composition.
Because of these a-typical kinetics, the elen~ent is unresponsive to glucose levels below about 1500 mg/liter, 20 and so is still quite light in color at 2000 mg/liter, the beginning of its intended use range; above this level, typical reaction kinetics occur, and higher glucose levels are readily quantitated. In contrast, any other system which displays more typical reaction kinetics will either 25 (a) be so dark at high'glucose levels that visual quantitation at high levels is difficult, or (b) be so unreactive in order still to be light in appearance at glucose levels of about 2000 mg/liter that again it will not - yield easily quantitated visual differences at various high 30 levels.
EXAMPLE
The example shown is merely illustratlve and not to be construed as a limit~tion of the invention. One skilled in the art will be able to make such variations, substitutions 35 and changes in the ingredients and parameters as may seem desirable. Peroxidase ~9105MR-horseradish)and glucose ~t~3~ L
oxidase (9400MRfrom Aspergillus niger) used in the e~amples were obtained from the Research Produc-ts Division, Mlles Laborator:ies, Inc., Elkhar-t/ IN. Gantrez AN 139 was obtained from GAF Corp., Chemical Products, ~.Y., N.~.
5 The activity of the enzyme preparation is measured by the number of units of activity per milligram of dry weight.
~he Commission on Enæymes of the International Union Oe Biochemistry has defined an International Unit (I.U.) of enzyme activity as 1 micromole (umol) of substrate utili~ed 10 per minute under specified ¢onditions of pll and temperature contro1.
Example I - Analytical Element for Glucose Assay In the experiments reported by this example arl analytical element was preparec~ by the method according to 15 the invention and tes~ed for its ability quantitatively to determine visually the presence of glucose in a liquid sample. Gantrez AN-139, a polycarboxylic anion (chemically it is the interpolymer of m@thyl vinyl ether and maleic anhydride), was added in the first dip. The Gantrez behaves 20 as a dye mordant, so forminy a complex, in the system, thereby protecting final colored reaction productO Ethyl cellulose in toluene was used as the second dip.
El~ment Preparation The solutions used in preparing the glucose specific 25 element contained the following components:
First Dip, for every 100 millilters (ml)
Likewise there i5 provided an analytical element and method for the determination of an analyte in a fluid sample which comprises contacting a sample with the analytical 25 element according to the invention and observing any resultant color change. The colored reaction product is produced within a time period of about 60-90 seconds after contact of the analytical element with the body fluid sample to be tested.
DESCRIPTION OF T~IE PRE~F~RRED EMB~DIMENTS
Although specific terms are used in the following description for the sake of clarity, these terms are intended to refer only to the particular embodiment of the 5 invention selected for exemplary illustration, and are no-t intended to define or limit the scope of the invention.
ANALYTE~RESPONSIVE COMPONENT
The analyte-responsive component comprises those reagents which interact with the analyte and/or resulting 10 products thereof to produce an oxidizing substance, e.g., hydrogen peroxide. In the presence of a peroxidatively active substance, which is one reagent of the analyte-responsive component, the oxidizing substance oxidizes the indicator to produce a detectable species 15 thereof.
rrhe indicator coupling agent comprises 4-aminoanti-pyrine~AAP) and 3,5-dichloro-2-hydroxy-benzene sulfo~ic acid and salts thereof. As an alternative, 3-hydroxy~2,4,6-triiod~benzoic acid (mw 515.8) can be 20 su~stituted for the 3,5-dichloro-2-hydroxy-benzene sulfonic acid.Attempts to use tetraalkylbenzidines as the indicator were unsuccessful because they lack the necassary reaction kinetics properties. 3-Methyl-2-benzothiazolinone hydrazone(MBTH3 with primiquine diphosphate was unsuitable.
25 4-aminoantipyrine with coupling agents 3-hydroxy-1,2,3,4-tetrahydrobenzo(n)quinoline(HTBQ~, methyl catechol, primiquine diphosphate and phenothiazine was also unsuitable.
The combination of 4-aminoantipyrine and 3,5-dichloro 30 2-hydroxy-benzene sulfonic acid, and the sodium or potassium salts thereof, performs successfully and best at particular ratios, as well as enzyme levels, buffer concentrations and polymer mo:rdants to monitor the color formation so that 3~
essentially no color is genera-ted with a glucose concentration less than 1800 mg/liter and then a sliyht peach color starts to form around 2000 mg/liter and continues to produce more color until 8000 mg/liter. As a result, good color resolution exists in every adjacent color block~
POLYMERIC MORDANT
Suitable polymeric mordants which can be used include poly(carboxylic acids) having the formula:
lo t (c~ c ~o ~ / n wherein R is a C1 Cl8 alkyl or amide, and n is an in-teger from 2 to the total number o~ repeating units of the polymer. Examples include polyacrylic acid and polyacrylamide copolymer.
Other polymeric mordants which can be used are copolymeric anhydrides having tne formula:
H R H H
C = C~ C = C
' O = C C ~
/
~1 wherein R i5 C1-Cl8 alkyl, ether, acetate or benzyl and n is an integer from 2 to the total number of repeating units of the polymer. Examples-include methyl vinyl e-ther maleic anhydride copolymer; vinyl acetate-maleic anhydride copolymer; ethylene-maleic anhvdride copo]ymer; octadecyl vinyl ether-maleic anhydride copolymer; and styrene maleic anhydride copolymer.
The polymeric mordant is preferably present in a concerltration o~ from about 0.5 to about 0.75 percen-t of the composition on a weight -to weight basis.
CARRIER
The term carrier refers -to matrices which are in-solu~le in and maintain their structural in~egrity when exposed to physiological or other liquid to be tested.
Suitable matrices which can be used include paper, cel-lulose, wood, synthetic resin fleeces, glass -Eiber, non-woven and woven fabrics, gelatin, various organic poly-mers, such as polypropylene/ and other organic materials well known as film ormers to those skilled in the art.
For convenience, th~ carrier can be suitably attached to an insoluble support or handle member which can be made from polystyrene~
ELEMENT PREPARATION
~s recited hereinabove, the test device is prepared by a process which comprises impregnating the carrier with a first solution having dissolved therein the indica-tor-coupling agent and a glucose oxidase-peroxidase. The glu-cose oxidase-peroxidase is described more fully in U.S.
Patent No. 4,361,648.
Using Whatman 3MM paper, the concentration of the 4-aminoantipyrine or salt thereof in the first solution is from about 5 to 40, preferably about lO to 30, and most preferably about 15 millimoles/liter(mmoles/liter), while the concentration of the 3,5-dichloro-2-hydroxy-benzene sulfonic acid or salt thereoE is from abou-t 0.5 to 500, preferably about 1 to 50, and mos-t pre~erably about 6 mmoles/liter.
* Trade Mark "~
The solution is advan~acJeously buEfered -to a p~l of ,about 5 to 8, preEerab~y about 7, employing a known noninterfering bu~fer such as tris~malonate. Citrate or any other buffer which will provide the same pH range can be 5 used.
Drying is of course eEfected as quickly as possible.
The second step in element preparation comprises impregnating the carrier with a solution of a semi-permeable polymer, such as ekhyl cellulose, in an organic solvent and 10 drying the carrierO The or~anic solvent preferably includes toluene. Particularly pref~rred is an organic solvent which includes toluene and ethanol. Where the solvent conslsts essentially of toluene ~nd ethanol, the toluene is Erom about 80 to 95 percent of the solvent and the ethanol is 15 from about 5 to a~out 20 percent of the solvent, the toluene and ethanol being together 100 percent on a volume/volume basis~
Suitable film-Eorming agents include other hydrophobic cellulose ethers and esters, the film serving to prevent 20 formed eleme,nts (red blood cell9~ from absorbing into the carrier during the period of use.
AN~LYTICAL PROCEDURE
The test device is advantageously used b,y momentarily dipping it in a test sample or by otherwise introducing a 25 test sample onto the carrier matrix, whereby a de-tectable color changè results when glucose is present. The volumetric capacity of khe carrier serves to limit the amount of sample absorbed thereby and to which the kest means incorporated therewith is exposed. Any excess sample 30 can be removed by washing the carrier to thereby limit the amount of sample tested to the volume thereof which has actually entered the carrier matrix. The liqui~ medium to M'~ 35 be assayed can be a naturally occurring or artificially formed liquid suspected to contain ~he ligand, and usually is a biologoical fluid or dilution thereof. siological _ fluids -that can be assayed includ,e serum, plasma, urine, 5 saliva, and amniotic and cerebrospinal fluids. The tes-t device can be used in the same way when samples of plasma, serum or o-ther body fluids are tested.
Semi quantitative results can be obtained using the analytical, elemen-t of the p~esen-t :inVentiOIl by compa-rlng tlle 10 color produced with a panel of standard colors ohtained with known concen-trations o~ analyte employing the same indicator~
The key issue invo~ving the chemistry of the novel elemen~s is -that i~ yields reaction kinetics which are lS atypical compared to tes-t systems with other indicators in solid or liquid-phase; and even the same components in liquid-phase or in solid-phase with a different composition.
Because of these a-typical kinetics, the elen~ent is unresponsive to glucose levels below about 1500 mg/liter, 20 and so is still quite light in color at 2000 mg/liter, the beginning of its intended use range; above this level, typical reaction kinetics occur, and higher glucose levels are readily quantitated. In contrast, any other system which displays more typical reaction kinetics will either 25 (a) be so dark at high'glucose levels that visual quantitation at high levels is difficult, or (b) be so unreactive in order still to be light in appearance at glucose levels of about 2000 mg/liter that again it will not - yield easily quantitated visual differences at various high 30 levels.
EXAMPLE
The example shown is merely illustratlve and not to be construed as a limit~tion of the invention. One skilled in the art will be able to make such variations, substitutions 35 and changes in the ingredients and parameters as may seem desirable. Peroxidase ~9105MR-horseradish)and glucose ~t~3~ L
oxidase (9400MRfrom Aspergillus niger) used in the e~amples were obtained from the Research Produc-ts Division, Mlles Laborator:ies, Inc., Elkhar-t/ IN. Gantrez AN 139 was obtained from GAF Corp., Chemical Products, ~.Y., N.~.
5 The activity of the enzyme preparation is measured by the number of units of activity per milligram of dry weight.
~he Commission on Enæymes of the International Union Oe Biochemistry has defined an International Unit (I.U.) of enzyme activity as 1 micromole (umol) of substrate utili~ed 10 per minute under specified ¢onditions of pll and temperature contro1.
Example I - Analytical Element for Glucose Assay In the experiments reported by this example arl analytical element was preparec~ by the method according to 15 the invention and tes~ed for its ability quantitatively to determine visually the presence of glucose in a liquid sample. Gantrez AN-139, a polycarboxylic anion (chemically it is the interpolymer of m@thyl vinyl ether and maleic anhydride), was added in the first dip. The Gantrez behaves 20 as a dye mordant, so forminy a complex, in the system, thereby protecting final colored reaction productO Ethyl cellulose in toluene was used as the second dip.
El~ment Preparation The solutions used in preparing the glucose specific 25 element contained the following components:
First Dip, for every 100 millilters (ml)
4-AAP 0.36 grams ~g) Gantrez (2%~ 25 ml Tris-~alonate Buffer,pH-~7.4 20 ml ~2 55 ml 3,5-Dichloro-2-hydroxy-benzene sulfonate sodium salt 0.12 g Peroxidase 0.2 g Glucose Oxidase (1000 IU/l) 6.0 ml Second Dip, for every 100 ml Ethocel (ethyl cellulose~ 1.5 g Toluene 95 ml Ethyl Alcohol S m]
MS-l2~5 ~ t,~
Reagent-contain,in~ Whatman 3MM filter paper (Whatman, Inc.~ Clifton, N.J.) is prepared by ~a) irnpreynatiny sheets of the paper to saturation with -thP first ~olu-tion and drying the paper at 60~ Centigrade (C) for 10 minutes; Ib) impregnating the paper of (a) to saturation with the second solution and drying at 40~C for 10 minutes.
The reagent-containing paper was cut to 0.5 cm ~centimeter) x 1.0 cm ~imensions and fixed to one end of a 0.5 cm x 8.25 cm polystyrene ilm by double-faced adhesive 10 tape, providing devices acc~r~ing to the invention. These were stored with a dessicant in brown glass bottles untll used.
Test Solution~
Fresh blood collected into evacuated collection tubes 15 containing ethylene diamine tetraacetic acid (EDTA~ was metabol,ically depleted of glucose by incubation at 37C
overnight ~16 - 20 hours). The hematocrit was adjusted to about 45%. Various glucose levels were prepared by adding various amoun~s of stock glucose (10% w/v) into the blood 20 samples.
Analytical Procedure The performance of the reagent device pxepared and incubated as above-describ~d was analyzed by the following procedure:
(a) A large drop of capillary or venous blood sufficient to cover each reagent area i~
applied to the test device.
(b~ Sixty seconds are allowed to elapse~
(c) Each reagent area is then ~ashed with water ~ufficien~ly to remove the blood sample.
M~
(d) Each reagent area is then blotted with a link-free paper towel.
(e) The low range pad or reagent(area) is then compared with color blocks in the range of 200 to 1,800 mg/liter. The color blocks for this range have a greenish, tint and if the color procluced falls betwe!en two colcr blocks the value is interpolated. If the color matche~ or exceeds the color of the 1,800 mg/liter color block, another 30 second~ is allowed to elapse before comparing the resulting color of the high range pad or reagent area with color blocks fcr the high range (2,000 to 8,000 mg/liter), ~5 again the interpolating if the color produced falls between two color blocks The high range color blocks have a peach or orange tint in contrast to the green tint of the low range color blocks.
20 Example II
Another suitable analytical element for the high range glucose levels was prepared by substitutiny in Example I
0.06g o 3-hydroxy-2,4,6-triiodobenzoic acid ~or the 3,5-dichloro-2-hydroxy-benzen sulfonate, sodium salt and substituting 0.18g of 4-AAP HCl for the 4-AAP. Essentially equivalent results were obtained.
It will be understood that the specification and examples are illustrative buk not limitative of the present invention an~ ~hat other embodiments within the spirit and scope oE the invention will suggesk themselves to khose
MS-l2~5 ~ t,~
Reagent-contain,in~ Whatman 3MM filter paper (Whatman, Inc.~ Clifton, N.J.) is prepared by ~a) irnpreynatiny sheets of the paper to saturation with -thP first ~olu-tion and drying the paper at 60~ Centigrade (C) for 10 minutes; Ib) impregnating the paper of (a) to saturation with the second solution and drying at 40~C for 10 minutes.
The reagent-containing paper was cut to 0.5 cm ~centimeter) x 1.0 cm ~imensions and fixed to one end of a 0.5 cm x 8.25 cm polystyrene ilm by double-faced adhesive 10 tape, providing devices acc~r~ing to the invention. These were stored with a dessicant in brown glass bottles untll used.
Test Solution~
Fresh blood collected into evacuated collection tubes 15 containing ethylene diamine tetraacetic acid (EDTA~ was metabol,ically depleted of glucose by incubation at 37C
overnight ~16 - 20 hours). The hematocrit was adjusted to about 45%. Various glucose levels were prepared by adding various amoun~s of stock glucose (10% w/v) into the blood 20 samples.
Analytical Procedure The performance of the reagent device pxepared and incubated as above-describ~d was analyzed by the following procedure:
(a) A large drop of capillary or venous blood sufficient to cover each reagent area i~
applied to the test device.
(b~ Sixty seconds are allowed to elapse~
(c) Each reagent area is then ~ashed with water ~ufficien~ly to remove the blood sample.
M~
(d) Each reagent area is then blotted with a link-free paper towel.
(e) The low range pad or reagent(area) is then compared with color blocks in the range of 200 to 1,800 mg/liter. The color blocks for this range have a greenish, tint and if the color procluced falls betwe!en two colcr blocks the value is interpolated. If the color matche~ or exceeds the color of the 1,800 mg/liter color block, another 30 second~ is allowed to elapse before comparing the resulting color of the high range pad or reagent area with color blocks fcr the high range (2,000 to 8,000 mg/liter), ~5 again the interpolating if the color produced falls between two color blocks The high range color blocks have a peach or orange tint in contrast to the green tint of the low range color blocks.
20 Example II
Another suitable analytical element for the high range glucose levels was prepared by substitutiny in Example I
0.06g o 3-hydroxy-2,4,6-triiodobenzoic acid ~or the 3,5-dichloro-2-hydroxy-benzen sulfonate, sodium salt and substituting 0.18g of 4-AAP HCl for the 4-AAP. Essentially equivalent results were obtained.
It will be understood that the specification and examples are illustrative buk not limitative of the present invention an~ ~hat other embodiments within the spirit and scope oE the invention will suggesk themselves to khose
5 skilled in the art.
Claims (11)
1. A method for preparing an analytical element for determining glucose in a liquid sample which method com-prises the steps of a) impregnating a carrier with a first solution hav-ing dissolved therein 4-aminoantipyrine or a salt thereof and 3-hydroxy-2,4,6-triiodobenzoic acid or 3,5-dichloro-2 hydroxy-benzene sulfonic acid, or a salt thereof, a glucose oxidase and a per-oxidase, and drying the carrier; and b) applying to the carrier a second solution of film-forming agent in a volatile solvent, and drying to remove the volatile solvent and leave a film over the dried first impregnant.
2. A method according to claim 1, wherein the con-centration of the 4-aminoantipyrine or salt thereof in the first solution is from about 5 to 40 mmoles/liter.
3. A method according to claim 1, wherein the con-centration of the 3-hydroxy-2,4,6-triiodobenzoic acid or 3,5-dichloro-2-hydroxy-benzene sulfonic acid, or salt thereof, in the first solution is from about 0.5 to 500 mmoles/liter .
4. A method according to claim 1, wherein the film-forming agent in the second solution is a hydrophobic cel-lulose ether or ester.
5. A method according to claim 1, wherein the first solution contains a buffer for maintaining a pH from about 5 to 8 and a mordant.
6. A method according to claim 5, wherein the con-centration of the 4-aminoantipyrine or salt thereof in the first solution is from about 10 to 30 mmoles/liter and the concentration of the 3,5-dichloro-2-hydroxy-benzene sulfonic acid or salt thereof in the first solu-tion is from about 1 to 50 mmoles/liter.
7. A method according to claim 5, wherein the con-centration of the 4-aminoantipyrine or salt thereof in the first solution is about 15 mmoles/liter, the concen-tration of the 3,5-dichloro-2-hydroxy-benzene sulfonic acid or salt thereof in the first solution is about 6 mmoles/liter, and the film-forming agent in the second solution is a hydrophobic cellulose ether or ester.
8. A method according to claim 5, wherein the 4-aminoantipyrine is present in the first solution as the hydrochloride, the sulfonic acid is present in the first solution as the sodium salt, the solvent in the first sol-ution is water, the pH of the first solution is about 7 and it contains a polymeric polycarboxylic acid or anhy-dride thereof as the mordant, and the film-forming agent in the second solution is ethyl cellulose.
9. An analytical element for determining whole blood glucose produced by the process of claim 1.
10. A method for determining the glucose content of whole blood within the range of about 2000 to 8000 mg/liter comprising contacting the whole blood with an analytical element produced by the process of claim 1, and matching the resulting color of the element with predetermined standards.
11. A system for determining the glucose content of whole blood over a range from about 0 to 8000 mg/liter comprising, in combination, an element for identifying a glucose content of up to about 2000 mg/liter, and the an-alytical element produced by the process of claim 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/388,123 US4427770A (en) | 1982-06-14 | 1982-06-14 | High glucose-determining analytical element |
| US388,123 | 1982-06-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1192821A true CA1192821A (en) | 1985-09-03 |
Family
ID=23532798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000425034A Expired CA1192821A (en) | 1982-06-14 | 1983-03-31 | High glucose-determining analytical element |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4427770A (en) |
| EP (1) | EP0101799B1 (en) |
| JP (1) | JPS596900A (en) |
| AR (1) | AR229910A1 (en) |
| AT (1) | ATE16820T1 (en) |
| AU (1) | AU540228B2 (en) |
| CA (1) | CA1192821A (en) |
| DE (1) | DE3361404D1 (en) |
| DK (1) | DK158645C (en) |
| ES (1) | ES523242A0 (en) |
| FI (1) | FI77894C (en) |
| IE (1) | IE55165B1 (en) |
| IL (1) | IL68312A0 (en) |
| IN (1) | IN159163B (en) |
| MX (1) | MX156030A (en) |
| NO (1) | NO162638C (en) |
| ZA (1) | ZA832503B (en) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4460684A (en) * | 1982-08-02 | 1984-07-17 | Miles Laboratories, Inc. | Ascorbate-resistant broad range glucose test composition, test device and method |
| DD247808C2 (en) * | 1984-04-09 | 1989-01-11 | Dresden Arzneimittel | TEST STRIPS FOR RECEIVING BLOOD SUGAR DAY PROFILES AND METHOD FOR THE PRODUCTION THEREOF |
| US4810633A (en) * | 1984-06-04 | 1989-03-07 | Miles Inc. | Enzymatic ethanol test |
| US4621049A (en) * | 1984-11-19 | 1986-11-04 | Miles Laboratories, Inc. | Enzymatic high range glucose test |
| DE3781008T2 (en) * | 1986-04-19 | 1993-04-15 | Sanwa Kagaku Kenkyusho Co | METHOD FOR MEASURING HYDROGEN PEROXIDE OR MEASURING A PEROXID-RELEASING ENZYME OR BIOCHEMICAL SUBSTRATE. |
| EP0243125B1 (en) * | 1986-04-19 | 1992-08-12 | Sanwa Kagaku Kenkyusho Co., Ltd. | Method of measuring phenol and alpha-naphthol, and method of measuring the activity of enzymes |
| DE3625852A1 (en) * | 1986-07-31 | 1988-02-04 | Miles Lab | IMPROVED TEST AGENTS AND METHOD FOR THE PRODUCTION THEREOF |
| DE68924098T2 (en) * | 1988-06-09 | 1996-04-18 | Abbott Lab | Process and device using covalently immobilized dyes. |
| US5264104A (en) * | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
| US5264105A (en) * | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
| US5320725A (en) * | 1989-08-02 | 1994-06-14 | E. Heller & Company | Electrode and method for the detection of hydrogen peroxide |
| JP2796150B2 (en) * | 1989-12-20 | 1998-09-10 | 株式会社ヤトロン | How to measure fructosamine |
| JPH04278450A (en) | 1991-03-04 | 1992-10-05 | Adam Heller | Biosensor and method for analyzing subject |
| US5593852A (en) * | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
| US5262305A (en) * | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
| US5211182A (en) * | 1991-10-23 | 1993-05-18 | Deutsch Marshall E | Home ovulation test kit and method |
| DE69809391T2 (en) * | 1997-02-06 | 2003-07-10 | Therasense Inc | SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION |
| US6103033A (en) * | 1998-03-04 | 2000-08-15 | Therasense, Inc. | Process for producing an electrochemical biosensor |
| US6134461A (en) | 1998-03-04 | 2000-10-17 | E. Heller & Company | Electrochemical analyte |
| US6175752B1 (en) * | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) * | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) * | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6949816B2 (en) * | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8480580B2 (en) * | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| EP1030931A4 (en) * | 1998-08-06 | 2004-05-26 | Syntron Biores Inc | Uric acid assay device with stabilized uricase reagent composition |
| US6753159B1 (en) | 1998-08-06 | 2004-06-22 | Jin Po Lee | Uric acid assay device with stabilized uricase reagent composition |
| US6251260B1 (en) | 1998-08-24 | 2001-06-26 | Therasense, Inc. | Potentiometric sensors for analytic determination |
| US6338790B1 (en) * | 1998-10-08 | 2002-01-15 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
| US6591125B1 (en) | 2000-06-27 | 2003-07-08 | Therasense, Inc. | Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator |
| JP4801301B2 (en) | 1999-06-18 | 2011-10-26 | アボット ダイアベティス ケア インコーポレイテッド | In vivo analyte sensor with limited mass transfer |
| US6616819B1 (en) * | 1999-11-04 | 2003-09-09 | Therasense, Inc. | Small volume in vitro analyte sensor and methods |
| US20060091006A1 (en) * | 1999-11-04 | 2006-05-04 | Yi Wang | Analyte sensor with insertion monitor, and methods |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US7041468B2 (en) * | 2001-04-02 | 2006-05-09 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| US6444169B1 (en) | 2001-06-18 | 2002-09-03 | Ralston Purina Company | Test-device for threshold glucose detection in urine |
| US6924154B2 (en) * | 2002-08-20 | 2005-08-02 | Quest Diagnostics Investments Incorporated | Hydrophilic chemilumescent acridinium labeling reagents |
| US7381184B2 (en) * | 2002-11-05 | 2008-06-03 | Abbott Diabetes Care Inc. | Sensor inserter assembly |
| ES2440284T3 (en) * | 2002-11-14 | 2014-01-28 | Thermo Fisher Scientific Biosciences Inc. | SiRNA directed to tp53 |
| US8771183B2 (en) | 2004-02-17 | 2014-07-08 | Abbott Diabetes Care Inc. | Method and system for providing data communication in continuous glucose monitoring and management system |
| US7811231B2 (en) | 2002-12-31 | 2010-10-12 | Abbott Diabetes Care Inc. | Continuous glucose monitoring system and methods of use |
| US8066639B2 (en) * | 2003-06-10 | 2011-11-29 | Abbott Diabetes Care Inc. | Glucose measuring device for use in personal area network |
| US7306641B2 (en) * | 2003-09-12 | 2007-12-11 | Hewlett-Packard Development Company, L.P. | Integral fuel cartridge and filter |
| USD914881S1 (en) | 2003-11-05 | 2021-03-30 | Abbott Diabetes Care Inc. | Analyte sensor electronic mount |
| JP2006153497A (en) * | 2004-11-25 | 2006-06-15 | Toshiba Corp | Preparation method of coating solution for glucose sensing film and manufacturing method of optical glucose sensor chip |
| US20070027381A1 (en) * | 2005-07-29 | 2007-02-01 | Therasense, Inc. | Inserter and methods of use |
| US9788771B2 (en) | 2006-10-23 | 2017-10-17 | Abbott Diabetes Care Inc. | Variable speed sensor insertion devices and methods of use |
| US20110060196A1 (en) * | 2009-08-31 | 2011-03-10 | Abbott Diabetes Care Inc. | Flexible Mounting Unit and Cover for a Medical Device |
| US7883464B2 (en) | 2005-09-30 | 2011-02-08 | Abbott Diabetes Care Inc. | Integrated transmitter unit and sensor introducer mechanism and methods of use |
| US20090105569A1 (en) | 2006-04-28 | 2009-04-23 | Abbott Diabetes Care, Inc. | Introducer Assembly and Methods of Use |
| US20110190603A1 (en) * | 2009-09-29 | 2011-08-04 | Stafford Gary A | Sensor Inserter Having Introducer |
| US8571624B2 (en) * | 2004-12-29 | 2013-10-29 | Abbott Diabetes Care Inc. | Method and apparatus for mounting a data transmission device in a communication system |
| US20110054275A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Mounting Unit Having a Sensor and Associated Circuitry |
| US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
| US9572534B2 (en) | 2010-06-29 | 2017-02-21 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
| US7731657B2 (en) | 2005-08-30 | 2010-06-08 | Abbott Diabetes Care Inc. | Analyte sensor introducer and methods of use |
| US9259175B2 (en) * | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
| US10226207B2 (en) | 2004-12-29 | 2019-03-12 | Abbott Diabetes Care Inc. | Sensor inserter having introducer |
| US8512243B2 (en) | 2005-09-30 | 2013-08-20 | Abbott Diabetes Care Inc. | Integrated introducer and transmitter assembly and methods of use |
| US9398882B2 (en) * | 2005-09-30 | 2016-07-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor and data processing device |
| US9743862B2 (en) | 2011-03-31 | 2017-08-29 | Abbott Diabetes Care Inc. | Systems and methods for transcutaneously implanting medical devices |
| US8333714B2 (en) * | 2006-09-10 | 2012-12-18 | Abbott Diabetes Care Inc. | Method and system for providing an integrated analyte sensor insertion device and data processing unit |
| US8112240B2 (en) * | 2005-04-29 | 2012-02-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing leak detection in data monitoring and management systems |
| US9521968B2 (en) * | 2005-09-30 | 2016-12-20 | Abbott Diabetes Care Inc. | Analyte sensor retention mechanism and methods of use |
| US20090054747A1 (en) * | 2005-10-31 | 2009-02-26 | Abbott Diabetes Care, Inc. | Method and system for providing analyte sensor tester isolation |
| US7766829B2 (en) * | 2005-11-04 | 2010-08-03 | Abbott Diabetes Care Inc. | Method and system for providing basal profile modification in analyte monitoring and management systems |
| EP1968432A4 (en) | 2005-12-28 | 2009-10-21 | Abbott Diabetes Care Inc | Medical device insertion |
| US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
| US7885698B2 (en) | 2006-02-28 | 2011-02-08 | Abbott Diabetes Care Inc. | Method and system for providing continuous calibration of implantable analyte sensors |
| US7620438B2 (en) | 2006-03-31 | 2009-11-17 | Abbott Diabetes Care Inc. | Method and system for powering an electronic device |
| US8226891B2 (en) | 2006-03-31 | 2012-07-24 | Abbott Diabetes Care Inc. | Analyte monitoring devices and methods therefor |
| US20090054749A1 (en) * | 2006-05-31 | 2009-02-26 | Abbott Diabetes Care, Inc. | Method and System for Providing Data Transmission in a Data Management System |
| WO2007143225A2 (en) * | 2006-06-07 | 2007-12-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
| GB0616566D0 (en) * | 2006-08-19 | 2006-09-27 | Rolls Royce Plc | An alloy and method of treating titanium aluminide |
| US8930203B2 (en) | 2007-02-18 | 2015-01-06 | Abbott Diabetes Care Inc. | Multi-function analyte test device and methods therefor |
| US8732188B2 (en) | 2007-02-18 | 2014-05-20 | Abbott Diabetes Care Inc. | Method and system for providing contextual based medication dosage determination |
| US8123686B2 (en) | 2007-03-01 | 2012-02-28 | Abbott Diabetes Care Inc. | Method and apparatus for providing rolling data in communication systems |
| US7928850B2 (en) | 2007-05-08 | 2011-04-19 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US20080281179A1 (en) * | 2007-05-08 | 2008-11-13 | Abbott Diabetes Care, Inc. | Analyte monitoring system and methods |
| US8461985B2 (en) * | 2007-05-08 | 2013-06-11 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
| US8665091B2 (en) * | 2007-05-08 | 2014-03-04 | Abbott Diabetes Care Inc. | Method and device for determining elapsed sensor life |
| WO2008150917A1 (en) | 2007-05-31 | 2008-12-11 | Abbott Diabetes Care, Inc. | Insertion devices and methods |
| US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
| US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
| US20100213057A1 (en) * | 2009-02-26 | 2010-08-26 | Benjamin Feldman | Self-Powered Analyte Sensor |
| US9226701B2 (en) * | 2009-04-28 | 2016-01-05 | Abbott Diabetes Care Inc. | Error detection in critical repeating data in a wireless sensor system |
| US9184490B2 (en) | 2009-05-29 | 2015-11-10 | Abbott Diabetes Care Inc. | Medical device antenna systems having external antenna configurations |
| WO2011025999A1 (en) * | 2009-08-29 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte sensor |
| WO2011026130A1 (en) * | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Inserter device including rotor subassembly |
| US9314195B2 (en) | 2009-08-31 | 2016-04-19 | Abbott Diabetes Care Inc. | Analyte signal processing device and methods |
| WO2011026148A1 (en) | 2009-08-31 | 2011-03-03 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods for managing power and noise |
| WO2011041469A1 (en) | 2009-09-29 | 2011-04-07 | Abbott Diabetes Care Inc. | Method and apparatus for providing notification function in analyte monitoring systems |
| WO2011041531A1 (en) | 2009-09-30 | 2011-04-07 | Abbott Diabetes Care Inc. | Interconnect for on-body analyte monitoring device |
| US20110082484A1 (en) * | 2009-10-07 | 2011-04-07 | Heber Saravia | Sensor inserter assembly having rotatable trigger |
| USD924406S1 (en) | 2010-02-01 | 2021-07-06 | Abbott Diabetes Care Inc. | Analyte sensor inserter |
| ES2881798T3 (en) | 2010-03-24 | 2021-11-30 | Abbott Diabetes Care Inc | Medical device inserters and medical device insertion and use procedures |
| US11064921B2 (en) | 2010-06-29 | 2021-07-20 | Abbott Diabetes Care Inc. | Devices, systems and methods for on-skin or on-body mounting of medical devices |
| US9980669B2 (en) | 2011-11-07 | 2018-05-29 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods |
| FI3300658T3 (en) | 2011-12-11 | 2024-03-01 | Abbott Diabetes Care Inc | Analyte sensor methods |
| US9968306B2 (en) | 2012-09-17 | 2018-05-15 | Abbott Diabetes Care Inc. | Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems |
| WO2016183493A1 (en) | 2015-05-14 | 2016-11-17 | Abbott Diabetes Care Inc. | Compact medical device inserters and related systems and methods |
| US10213139B2 (en) | 2015-05-14 | 2019-02-26 | Abbott Diabetes Care Inc. | Systems, devices, and methods for assembling an applicator and sensor control device |
| CN110461217B (en) | 2017-01-23 | 2022-09-16 | 雅培糖尿病护理公司 | Systems, devices, and methods for analyte sensor insertion |
| US20210115495A1 (en) * | 2017-04-18 | 2021-04-22 | Sun Chemical Corporation | Printed test strips to determine glucose concentration in aqueous liquids |
| WO2023172715A1 (en) | 2022-03-11 | 2023-09-14 | Sun Chemical Corporation | Method of determining glucose concentration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5425892A (en) | 1977-07-29 | 1979-02-27 | Wako Pure Chem Ind Ltd | Quantitative determination of hydrogen peroxide |
| US4098574A (en) | 1977-08-01 | 1978-07-04 | Eastman Kodak Company | Glucose detection system free from fluoride-ion interference |
| US4247631A (en) | 1979-01-31 | 1981-01-27 | Millipore Corporation | Reagent and method for the analytic determination of hydrogen peroxide |
| US4291121A (en) * | 1979-04-13 | 1981-09-22 | Miles Laboratories, Inc. | Bilirubin-resistant determination of uric acid and cholesterol |
| IT1130252B (en) | 1980-02-04 | 1986-06-11 | Elvi Spa | METHOD FOR THE ELIMINATION OF BILIRIBUNA INTERFERENCE IN THE DOSAGE OF HYDROGEN PEROXIDE THROUGH A MODIFIED TRINDER REACTION |
| US4303753A (en) | 1980-03-20 | 1981-12-01 | Miles Laboratories, Inc. | Method and device for the semiquantitative determination of glucose in aqueous fluids |
| US4361648A (en) * | 1981-08-13 | 1982-11-30 | Miles Laboratories, Inc. | Color fixed chromogenic analytical element |
-
1982
- 1982-06-14 US US06/388,123 patent/US4427770A/en not_active Expired - Lifetime
-
1983
- 1983-03-31 CA CA000425034A patent/CA1192821A/en not_active Expired
- 1983-04-06 AU AU13187/83A patent/AU540228B2/en not_active Ceased
- 1983-04-06 IL IL68312A patent/IL68312A0/en unknown
- 1983-04-11 ZA ZA832503A patent/ZA832503B/en unknown
- 1983-04-20 AR AR292762A patent/AR229910A1/en active
- 1983-05-23 IN IN336/DEL/83A patent/IN159163B/en unknown
- 1983-06-02 NO NO831986A patent/NO162638C/en unknown
- 1983-06-03 DE DE8383105500T patent/DE3361404D1/en not_active Expired
- 1983-06-03 EP EP83105500A patent/EP0101799B1/en not_active Expired
- 1983-06-03 AT AT83105500T patent/ATE16820T1/en not_active IP Right Cessation
- 1983-06-10 JP JP58102982A patent/JPS596900A/en active Granted
- 1983-06-10 MX MX197619A patent/MX156030A/en unknown
- 1983-06-10 FI FI832096A patent/FI77894C/en not_active IP Right Cessation
- 1983-06-13 DK DK270683A patent/DK158645C/en not_active IP Right Cessation
- 1983-06-13 IE IE1383/83A patent/IE55165B1/en not_active IP Right Cessation
- 1983-06-14 ES ES523242A patent/ES523242A0/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| EP0101799B1 (en) | 1985-12-04 |
| DK270683D0 (en) | 1983-06-13 |
| NO162638B (en) | 1989-10-16 |
| DE3361404D1 (en) | 1986-01-16 |
| DK158645B (en) | 1990-06-25 |
| IL68312A0 (en) | 1983-07-31 |
| DK270683A (en) | 1983-12-15 |
| MX156030A (en) | 1988-06-16 |
| ZA832503B (en) | 1984-06-27 |
| EP0101799A1 (en) | 1984-03-07 |
| JPS596900A (en) | 1984-01-13 |
| AU1318783A (en) | 1984-01-05 |
| FI832096L (en) | 1983-12-15 |
| FI77894C (en) | 1989-05-10 |
| IN159163B (en) | 1987-04-04 |
| NO162638C (en) | 1990-01-24 |
| ES8405153A1 (en) | 1984-05-16 |
| AU540228B2 (en) | 1984-11-08 |
| AR229910A1 (en) | 1983-12-30 |
| ES523242A0 (en) | 1984-05-16 |
| FI77894B (en) | 1989-01-31 |
| IE55165B1 (en) | 1990-06-20 |
| US4427770A (en) | 1984-01-24 |
| ATE16820T1 (en) | 1985-12-15 |
| NO831986L (en) | 1983-12-15 |
| FI832096A0 (en) | 1983-06-10 |
| JPH0355120B2 (en) | 1991-08-22 |
| DK158645C (en) | 1990-11-19 |
| IE831383L (en) | 1983-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1192821A (en) | High glucose-determining analytical element | |
| US4361648A (en) | Color fixed chromogenic analytical element | |
| EP0025227B1 (en) | Precursor indicator compositions | |
| CA1290661C (en) | Stable composition for the determination of peroxidatively active substances | |
| EP0985930B1 (en) | Visual blood glucose test strip | |
| CN1207393C (en) | Reagent test strip for analyte determination | |
| US5460777A (en) | Analytical element for whole blood analysis | |
| CA1048390A (en) | Method, composition, and device for determining the specific gravity of a liquid | |
| EP0256562B1 (en) | Dry-type multilayer analytical element | |
| US4594224A (en) | Analytical element | |
| JPH0476630B2 (en) | ||
| US6962819B1 (en) | Method of measuring analyte using dry analytical element | |
| EP0036563B1 (en) | Bilirubin-resistant composition for the determination of cholesterol, test device containing the composition and method of making the test device | |
| US5336599A (en) | Method of measuring analyte using dry analytical element | |
| CA1278243C (en) | Analytical element containing photosensitive compound and filter layer and method of use | |
| EP0244825A1 (en) | Dry-type analytical element for cholesterol | |
| JPS61177997A (en) | Analytical element | |
| GB2049180A (en) | Bilirubin-resistant determination of uric acid | |
| EP1162451B1 (en) | Dry measuring test device | |
| JPH05260994A (en) | Detection of analyte in saliva using peroxide-peroxidase test system | |
| JPH0522520B2 (en) | ||
| CS214658B2 (en) | Means for detecting the presence of the component of tested sample | |
| AU5878896A (en) | Use of a salt of 6-carboxy-3-methylbenzothiazolone hydrazone hydrate in colorimetric determination of hydrogen peroxide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry | ||
| MKEX | Expiry |
Effective date: 20030331 |